Traws Pharma Inc (TRAW) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.49 (-8.50%), Market cap $0.03B, P/E ratio 2.29, 52-week low–high $1.09 ~ $3.13.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is adm
Financial statements, price targets, institutional (13F) holdings and related news for Traws Pharma Inc are updated in real time on BlackAll Trade.
Traws Pharma Inc trades at $0.49 (-8.50%). Real-time quotes and charts are available on BlackAll Trade.
Traws Pharma Inc has a market cap of about $0.03B. Its P/E ratio is 2.29.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies